Jennifer R. Grandis, MD, FACS
Professor of Otolaryngology and Pharmacology



Dr. Grandis is a Distinguished Professor of Otoalryngology and a member of the Cellular and Molecular Pathology Graduate Training Program.
Office Location:
Eye & Ear Institute, Suite 500
200 Lothrop Street
Pittsburgh, PA 15213 		Contact Information:
Office Telephone: 412-647-5280
Lab Telephone: 412-383-5405
Fax: 412-647-2080
Email: jgrandis@pitt.edu

Education

  • BS - 1982, Swarthmore College
  • MD - 1987, University of Pittsburgh

Clinical Expertise

Otolaryngology

Research Interests

  • Signal transduction
  • Gene therapy
  • Personalized medicine

Certifications

Diplomate, American Board of Otolaryngology - 1994

Specialties

Otolaryngology

Selected Publications

View Dr. Grandis' publications on PubMed

Bhola NE, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, Argiris A, Seethala R, Grandis JR. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clinical Cancer Research. 2011 Aug 1; 17(15): 4996-5004. Epub 2011 Jun 8. PMID: 21653688. PMCID: PMC3149755 [Available on 2012/8/1].

Vaezi A, Wang XZ, Buch S, Gooding W, Wang L, Seethala RR, Weaver DT, D’Andrea AD, Argiris A, Romkes M, Niedernhofer LJ, Grandis JR. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clinical Cancer Research. 2011 Aug 15; 17(16): 5513-22. DOI: 10.1158/1078-0432. CCR-11-0086. Epub 2011 Jul 7. PMID: 21737503. PMCID: PMC3156890.

Stransky N, Egloff AM, Tward A, Kostic A, Cibulskis K, Sivachenko A, Kryukov G, Lawrence M, Sougnez C, McKenna A, Ramos AH, Stojanov P, Carter SL, Voet D, Cortes M, Auclair D, Saksena G, Guiducci C, Onofrio R, Parkin M, Romkes M, Weissfeld J, Seethala RR, Wang L, Winckler W, Ardlie K, Gabriel SB, Myerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046): 1157-60. Epub 2011 Jul 28. PMID: 21798893. PMC Journal-In Process.

Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clinical Cancer Research. 2011 Sep 15; 17(18): 5935-44. Epub 2011 Jul 26. PMID: 21791633. PMC Journal-In Process.

Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin N. Assembly And Initial Characterization Of A Panel Of 85 Genomically Validated Cell Lines From Diverse Head And Neck Tumor Sites. Clinical Cancer Research. 2011 Dec 1; 17(23): 7248-64. Epub 2011 Aug 25. PMID: 21868764. PMCID: PMC3229662 [Available on 2012/12/1].

Glazer P, Grandis JR, Powell S, Brown M, Helleday T, Bristow R, Powis G, Hill RP, Le TQ, Pelroy R, Mohla S, Bernhard EJ. Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities. Radiation Research. 2011 Sep; 176(3): e0016-21. Epub 2011 Jul 8. PMID: 21740251. PMC Journal-In Process.

Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis JR, Egloff AM. Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Investigational New Drugs. 2011 Sep 1. [Epub ahead of print]. PMID: 21881918. PMC Journal-In Process.

Zhong S, Nukui T, Buch S, Diergaarde B, Weissfeld LA, Grandis JR, Romkes M, Weissfeld JL. Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent. Cancer, Epidemiology, Biomarkers & Prevention. 2011 Nov; 20(11): 2429-37. Epub 2011 Sep 2. PMID: 21890746. PMCID: PMC3210907 [Available on 2012/11/01].

Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BF 4th, Seethala R, Wang L, Gooding W, Grandis JR, Ferris RL. Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncology, 2011 Oct; 47(10): 961-6. Epub 2011 Sep 1. PMID: 21889392. PMC Journal-In Process.

Park B, Chiosea S, Grandis JR. Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomarkers. 2011; 9(1-6): 325-39. PMID: 22112483. PMC Journal-In Process.

Dedhia RC, Grandis JR, Fontes PA, Johnson JT, Weissfeld J. Screening for Head and Neck Cancer in Liver Transplant Candidates: A Review of 11 Years Experience at the University of Pittsburgh. Laryngoscope. 2012 Mar; 122(3): 539-42. doi: 10.1002/lary.22406. Epub 2011 Dec 19. PMID: 22183711. NIHMS383093. PMC Journal-In Process.

Egloff AM, Lui X, Gaither Davis AL, Trevelline BK, Vuga MM, Siegfried JM, Grandis JR. Elevated Gastrin-Releasing Peptide Receptor mRNA expression in buccal mucosa: Association with head and neck Squamous cell carcinoma. Head & Neck. 2012 Mar 20. DOI: 10.1002/hed.22963. [Epub ahead of print]. PMID: 22431275. PMC Journal-In Process.

Egloff AM, Davis AG, Shuai Y, Land S, Pilewski JM, Luketich JD, Landreneau R, Miller YE, Grandis JR, Siegfried JM. Gastrin-Releasing Peptide Receptor Expression in Non-Cancerous Bronchial Epithelia Is Associated with Lung Cancer: a Case-Control Study. Respiratory Research. 2012 Feb 1; 13(1): 9. [Epub ahead of print]. PMID: 22296774. PMC Journal-In Process.

Klein JD, Christopoulos A, Ahn SM, Gooding WE, Grandis JR, Kim S. Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. Head & Neck. 2012 Feb 6. doi: 10.1002/hed.21917. {Epub ahead of print]. PMID: 22307735. PMC Journal-In Process.

Wheeler SE, Siwak DR, Chai RL, Lavalle CR, Seethala RR, Wang L, Cieply KM, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM. Tumor epidermal growth factor receptor (EGFR) and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clinical Cancer Research. 2012 Feb 20. [Epub ahead of print]. PMID: 22351687. PMC Journal-In Process.

Wheeler SA, Morariu E, Bednash J, Seethala RR, Chiosea SI, Grandis JR. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clinical Cancer Research. 2012 May 15; 18(10): 2850-60. Epub 2012 Apr 6. PMID: 22490227. PMC Journal-in process.

Bhola N, Sahu A, Freilini M, Cassell A, Chen CS, Grandis JR. Anti-tumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Molecular Cancer Therapeutics. 2012 May 23. [Epub ahead of print]. PMID: 22491800.

Lui VWY, Grandis JR. Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer. In press. Head and Neck Pathology, 2012.

Duvvuri U, Gollin S, Xiao D, Grandis JR. TMEM16A, induces MAPK and contributes directly to tumorigenesis and cancer progression. In press. Cancer Research, 2012.

Quesnelle KM, Wheeler SA, Ratay M, Grandis JR. Preclinical Modeling of EGFR Inhibitor Resistance in Head and Neck Cancer. In press. Cancer Biology & Therapy, 2012.

Moskowitz H, Gooding WE, Thomas SM, Freilino ML, Argiris E, Ferris R, Gross N, Grandis JR. Serum Biomarker Modulation Following Molecular Targeting of Epidermal Growth Factor and Cycloxygenase Pathways: a Pilot Randomized Trial in Head and Neck Cancer. In press. Oral Oncology, 2012.

Sen M, Thomas SM, Sahu N, Chen X, Joyce S, Rapireddy S, Shi H, Yeh Ji, Li C, Johnson DE, Ly D, Grandis JR. Development of a transcription factor decoy targeting STAT3 for systemic administration as cancer therapy. In press. Cancer Discovery 2012.